Aurora Cannabis (ACB) Cash & Equivalents (2018 - 2026)

Aurora Cannabis (ACB) has reported Cash & Equivalents for 9 consecutive years, with $47.2 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 50.92% year-over-year to $47.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.2 million (down 50.92% YoY) and the FY2026 annual result came in at $46.8 million, down 52.82% from the prior year.
• Cash & Equivalents rose to $47.2 million in Q1 2026 per ACB's latest filing, from $40.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ACB reached as high as $343.4 million in Q2 2022 and fell as low as $40.4 million in Q4 2025.
• A 5-year average of $140.9 million and a median of $101.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents grew 0.15% — and 2023, when it tumbled 66.04%.
• Year by year, Cash & Equivalents stood at $190.6 million in 2022, then slumped by 44.36% to $106.0 million in 2023, then declined by 10.47% to $94.9 million in 2024, then plunged by 57.43% to $40.4 million in 2025, then rose by 16.71% to $47.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $47.2 million, $40.4 million, and $69.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.